Drug Monitoring
Less toxic lithium treatment for major depressive disorder set for phase 2a study
A potential next-generation lithium treatment is set to be tested in major depressive disorder after the FDA issued a “study may proceed” letter for a phase 2a trial of AL001 by Alzamend Neuro.
Triple therapy shows safety, tolerability for older children with cystic fibrosis
In kids aged 6 years and older with cystic fibrosis and either F508del/minimal function or F508del/F508del genotypes, elexacaftor/tezacaftor/ivacaftor was safe and well tolerated for up to 120 weeks, according to study results.
Antifungal therapeutic drug monitoring adherence high, though room for improvement exists
A recent survey showed moderate to high adherence for antifungal therapeutic drug monitoring adherence, though there was room for improvement, specifically when using certain antifungals as prophylaxis.
Next-generation lithium treatment for bipolar disorder to be studied
A potential new lithium treatment for bipolar disorder, designed to avoid toxicities currently associated with the substance, is set to undergo a phase 2 study.
FDA grants de novo status to ‘5-minute’ drug monitoring tests for Humira, Remicade in IBD
The FDA has granted de novo clearance to ProciseDx Inc. for its therapeutic drug monitoring tests for Humira and Remicade, as well as their biosimilars, in patients with inflammatory bowel disease, according to a company release.
VIDEO: Point-of-care, drug-level assays help predict ‘best time, best dose’ in IBD therapy
DENVER — In a Healio video exclusive, Alan Moss, MD, discusses his presentation at the Crohn’s and Colitis Congress, which detailed the use of therapeutic drug monitoring in the management of patients with inflammatory bowel disease.
EULAR: Routine, proactive therapeutic drug monitoring unnecessary in RMDs
Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.
Minimal monitoring induces sustained virological response in HCV
Among patients treated with sofosbuvir and velpatasvir for hepatitis C virus, the minimal monitoring approach achieved sustained virological response similar to standard monitoring, according to research.
Therapeutic drug monitoring sustains disease control during infliximab maintenance
Proactive therapeutic drug monitoring sustained disease control without disease worsening among patients with immune-mediated inflammatory diseases undergoing infliximab maintenance therapy, according to study results.
Maintenance infliximab more effective with therapeutic drug monitoring
Therapeutic drug monitoring, in which serum levels are regularly checked to adjust dose and intervals, is more effective at controlling disease than standard therapy with infliximab, according to data presented at ACR Convergence 2021.